Alivus Life Sciences Limited (BOM:543322)

Market Cap	171.81B +52.3%
Revenue (ttm)	25.90B +7.9%
Net Income	6.03B +21.7%
EPS	49.03 +21.6%
Shares Out	n/a
PE Ratio	28.56
Forward PE	22.39
Dividend	5.00 (0.36%)
Ex-Dividend Date	Sep 1, 2026

Volume	16,204
Open	1,343.15
Previous Close	1,343.45
Day's Range	1,332.65 - 1,407.05
52-Week Range	830.00 - 1,495.30
Beta	n/a
Analysts	Strong Buy
Price Target	1,432.25 (+2.27%)
Earnings Date	Oct 29, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,272
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In fiscal year 2026, Alivus Life Sciences's revenue was 25.52 billion, an increase of 6.91% compared to the previous year's 23.87 billion. Earnings were 5.64 billion, an increase of 16.24%.

Analyst Summary

According to 4 analysts, the average rating for 543322 stock is "Strong Buy." The 12-month stock price target is ₹1,432, which is an increase of 2.27% from the latest price.

Price Target

₹1,432

(2.27% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 28, 2026

Data Sources Report a data error